


Manufacturing Cell Therapies – The BMS Difference

Innovation in manufacturing to deliver on the future of cell therapies


Manufacturing of autologous cell therapies requires a personalized process, with each therapy created from an individual patient’s cells. Bristol Myers Squibb is advancing cell therapy research through novel manufacturing approaches and a well-established supply chain platform across a broad network of state-of-the-art facilities with cutting-edge technologies and highly trained manufacturing teams. With a focus on innovations that drive the most meaningful advances, BMS is utilizing automation, digitization and next-generation manufacturing technology to prepare for commercializing cell therapies for patients in need.

Cell Therapy Manufacturing Footprint & Network



5 state-of-the-art cell therapy manufacturing facilities to meet global patient demand with a Devens, MA site under construction and an EU site in selection phase


~2000 talented and passionate people, working together with agility and urgency to deliver on the promise of cell therapy to patients



Unique portfolio with **5** investigational cell therapies in clinical trials with a growing early R&D portfolio



Reliable manufacturing processes across the portfolio have delivered cell therapies to **~1500** patients globally in clinical trials




Working in partnership with strategic external collaborations to shape the next wave of innovation in cell therapy



Our Strategies Support Today's Needs & Future Innovation

- 1 Develop **reliable, quality supply & build capacity** across **robust global network**
- 2 Leverage **technology and innovation for continuous improvement** to reduce complexity, decrease turnaround time and cost, and improve product control

Paradigm-shifting manufacturing platforms, including:




Optimization of current generation of cell therapies with state-of-the-art expansion manufacturing platform built on learnings from partner institutions and use of translational data and new technologies

NEX-T manufacturing platform, designed to produce CAR T cell therapies faster and with a higher level of product control



Continued investment in new manufacturing platforms to deploy technologies to address resistance to CAR T cell therapies, expanding into solid tumors and creating allogeneic ("off-the-shelf") CAR T cell therapies

Our Leading Role In Advancing Cell Therapy Research For Patients



At BMS, every cell therapy product we manufacture represents a unique cancer patient. We are **committed to working smarter, faster and better** to transform patient lives through science.

